First Trust Advisors LP Lowers Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

First Trust Advisors LP lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 321,215 shares of the specialty pharmaceutical company's stock after selling 15,812 shares during the quarter. First Trust Advisors LP owned about 0.53% of Jazz Pharmaceuticals worth $39,558,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. LSV Asset Management lifted its stake in Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after purchasing an additional 37,108 shares during the last quarter. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Jazz Pharmaceuticals by 4.8% during the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after buying an additional 72,007 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 15.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after acquiring an additional 83,807 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at $54,487,991.25. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $0.55 during midday trading on Wednesday, reaching $116.96. The company's stock had a trading volume of 1,127,197 shares, compared to its average volume of 801,788. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $7.10 billion, a P/E ratio of 16.47, a PEG ratio of 1.04 and a beta of 0.42. The firm has a 50 day moving average price of $123.41 and a 200-day moving average price of $122.36. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Analyst Ratings Changes

A number of brokerages have issued reports on JAZZ. Truist Financial upped their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Barclays reiterated an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Morgan Stanley reissued an "overweight" rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.